Optimal Value-Based Therapy

Ken Schaecher, MD

Video Categories: Polycythemia Vera

Listen as Ken Schaecher, MD discusses the optimal value-based therapy for treatment of polycythemia vera.

Supported through funding from Incyte

Related Videos

August 29, 2018

How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.

July 13, 2021

Real-World Management of Thyroid Cancer with TRK Inhibitors

Dr Ezra Cohen of UC San Diego, La Jolla, CA, and Dr Mary Fidler of Rush University Medical Center, Chicago, IL, recount their clinical experiences and the journeys of patients treated with TRK inhibitors for thyroid cancer.